DXC018 / Hangzhou DAC Biotech - LARVOL DELTA

DXC018: A novel HER2 dual-payload bispecific ADC with promising potential for gastrointestinal cancers and other solid tumors (AACR 2025) - "These findings suggest that DXC018, by leveraging dual HER2 binding and the complementary mechanisms of the antimetabolite and the topoisomerase I inhibition, offers significant therapeutic potential for the treatment of gastrointestinal malignancies and the other solid tumors. This innovative dual-action design establishes DXC018 as a promising next-generation ADC to address unmet needs in gastrointestinal cancers."

Gastrointestinal Cancer • Oncology • Solid Tumor • HER-2